Ubrelvy (ubrogepant) was approved by the U.S. Food and Drug Administration (FDA) on December 20, 2019 [1].
What is Ubrelvy used for?
Ubrelvy is a medication used to treat acute migraine with or without aura in adults [1]. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [1].
How does Ubrelvy work?
Ubrelvy works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [1]. By inhibiting CGRP, the drug helps to reduce inflammation and pain associated with migraine attacks [1].
What is the difference between Ubrelvy and other migraine treatments?
Unlike traditional acute migraine treatments such as triptans, Ubrelvy does not cause vasoconstriction, which is a narrowing of blood vessels [2]. This difference in mechanism may make it a suitable option for individuals with certain cardiovascular risk factors for whom triptans are not recommended [2]. Other CGRP antagonists available for migraine treatment include Nurtec ODT (rimegepant) and Zavzpret (zavegepant) nasal spray [3, 4].
When does Ubrelvy patent exclusivity expire?
Information regarding the patent expiry of Ubrelvy is available through specialized patent databases [5]. DrugPatentWatch.com tracks patent information for various drugs, including Ubrelvy [5].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie [1].
What are the potential side effects of Ubrelvy?
Common side effects of Ubrelvy include nausea, fatigue, and dry mouth [1]. Less common side effects can include abdominal pain and rash [1]. It is important to discuss any potential side effects with a healthcare provider [1].
What clinical data supports Ubrelvy's use?
The FDA approval of Ubrelvy was based on data from two randomized, placebo-controlled clinical trials, PROGRESS 1 and PROGRESS 2 [1]. These trials demonstrated that Ubrelvy was effective in reducing migraine pain and the most bothersome symptoms associated with migraine [1].
Sources:
1. https://www.fda.gov/drugs/drug-approvals/fda-approves-ubrelvy-ubrogepant-migraine
2. https://www.drugpatentwatch.com/drug/ubrelvy
3. https://www.drugpatentwatch.com/drug/nurtec-odt
4. https://www.drugpatentwatch.com/drug/zavzpret
5. https://www.drugpatentwatch.com/